Open Menu

Navigate Compliance Waters

Widler & Schiemann AG can provide you with innovative, creative and cost effective answers to your questions and needs in the areas of Clinical Quality Management. With our vast experience and extensive network in the industry and the regulators we are uniquely positioned to identify and provide the best solutions for you.

Servicehandout:

Download as PDF
  • 20 March 2017
  • 2404
CFDA sets out principles for generic equivalency clinical trials
Follow up to last years’ release of new Bioequivalence guidelines
Read more online Read
  • 16 March 2017
  • 1032
FDA publishes OSI Statistics
OSI (Office of Scientific Investigations) publishes an overview of metrics on their homepage
Read more online Read
  • 12 March 2017
  • 8479
Over 1,000 studies now recorded in EU register of post-authorisation studies
EU PAS Register increases transparency of research in medicines after they have been authorised in the EU
Read more online Read
  • 08 March 2017
  • 2122
EMA invites comment on revised “Document Access Policy”
Comments from stakeholders invited until 18 May 2017
Read more online Read
  • 04 March 2017
  • 1532
ICH invites comments on Efficacy Guidelines
ICH Reflection on “GCP Renovation”: Modernization of ICH E8 and Subsequent Renovation of ICH E6
Read more online Read
  • 01 March 2017
  • 903
US Government publishes revision for the protection of human subjects
Widler & Schiemann’s interpretation of the new policy
Read the pdf Read
  • 18 November 2016
  • 188
Global GCP Guideline Amendment Adopted!
This amendment will now be implemented by ICH members through national and regional guidance
Read the ICH Press Release
  • 30 September 2016
  • 1564
Chinese Manufacturers struggle with Quality
While Chinese companies export about 50% of global APIs they struggle with international quality requirements
Read more online Read
  • 20 September 2016
  • 1401
Transparency in drug regulation
Publication of assessment reports in Europe and Australia makes information on medicines more easily available
Read more online Read
  • 16 September 2016
  • 1297
EU collaboration strengthens safety monitoring of medicines
European Commission publishes three-year report on implementation of pharmacovigilance legislation
Read more online Read
  • 08 September 2016
  • 1414
Better monitoring of biological medicines
New chapter in guidelines on good pharmacovigilance practices
Read more online Read
  • 04 September 2016
  • 1444
CFDA sets out punishments for counterfeit clinical trial data
Chinese authorities try to go against this trend by enforcing new legislations of punishment and fines
Read the pdf Read
  • 20 August 2016
  • 1490
FDA issues draft guidance on drug development in rare diseases
This draft guidance is open for comments for the next 60 days.
Read the pdf Read
  • 15 August 2016
  • 1637
EMA publishes Pharmacovigilance Report
Annual report of pharmacovigilance inspectors’ working party for 2014
Read the pdf Read
  • 10 August 2016
  • 1673
Audits in GCP and Beyond
The third issue of GCP auditing will be released soon
Read more online Read
  • 05 August 2016
  • 1728
UK TAKES AIM AT PHARMA PERKS
Sunshine rule announced in the UK
Read
  • 31 July 2016
  • 1589
CFDA issues extensive DRR draft amendments
The China FDA invites comments on their latest revision of their Drug Registration Regulation
Read the pdfRead more online Read
  • 31 July 2016
  • 1665
European Commission launches EU-U.S. Privacy Shield
A new framework for stronger protection for transatlantic data flow to build trust
Read more online Read
  • 31 July 2016
  • 1469
EMA to introduce Public Hearings
Vox Populi at EMA’s PRAC
Read the pdf Read
  • 31 July 2016
  • 1466
EMA plans to revise guidance on first-in-human clinical trials
Comments invited on a concept paper on changes intended to support best practices
Read
  • 21 March 2016
  • 1538
Draft Guidance on format of the Risk Management Plan (RMP) in the EU – in integrated format
The European Medicines Agency is consulting stakeholders on an amended risk management plan (RMP) template, to be used by medicine developers.
Read more online Read
  • 14 March 2016
  • 1733
EMA publishes two Drug Safety related Draft Guidance for Consultation
Guideline on Good Pharmacovigilance Practices (GVP) 3 - Module V – Risk management systems (Rev 2)
Read the pdfRead more online Read
  • 07 March 2016
  • 1771
FDA issues new Guidance on Safety Data in late Stage Trials
Determining the Extent of Safety Data Collection Needed in Late-Stage Premarket and Postapproval Clinical Investigations
Read the pdf Read
  • 03 March 2016
  • 2126
Oliver Hellstern, MD joins Widler & Schiemann
Oliver Hellstern, Expert in Drug Safety, joins Widler & Schiemann Ltd. on March 1st, 2016
Read more online Read
  • 22 February 2016
  • 1849
Stronger data protection rules for Europe
The EU adopts the data protection reform package
Read more online Read
  • 15 February 2016
  • 1915
EMA launches new IT System
On 1 February 2016, the Agency is launching a new IT system to answer stakeholders’ IT-related queries and services.
Read
  • 10 February 2016
  • 1825
Germany: New Anti-Corruption Law
Fighting Private Sector Bribery and Cross-Border Corruption
Read more online Read
  • 09 February 2016
  • 1927
EMA delays enforcement of new Clinical Trial Regulation
EMA will not enforce the new Clinical Trial Regulation as planned in May 2016 – 2017 is more likely
Read more online Read
  • 09 February 2016
  • 2097
New FDA Draft Guidance on Safety Assessment for IND Safety Reporting
The new Draft Guidance on Safety Assessment for IND Safety Reporting is open for comments to be sent to FDA
Read the pdf Read
  • 21 January 2016
  • 1827
Endpoint Adjudication Survey Results are in!
The recently launched endpoint adjudication survey results are out:
Read more online Read
  • 14 January 2016
  • 2223
EMA aims to reinforce compliance with good clinical practice
Regulatory information - Replacement of GCP non-compliant pivotal studies in centralised marketing-authorisation applications not accepted
Read more online Read
  • 07 January 2016
  • 1628
New FDA Guidance on meetings with Biosimilar Companies
Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants: Guidance for Industry
Read the pdf Read
  • 06 January 2016
  • 1739
FDA issues new Draft Guidance on Communication between Sponsors and FDA
Best Practices for Communication Between IND Sponsors and FDA During Drug Development-Guidance for Industry and Review Staff
Read the pdf Read
  • 20 December 2015
  • 1942
Beat Widler to present at the 2nd Academic Symposium
Beat Widler is invited to speak on the Clinical Research Quality & China New Drug 50 Roundtable Forum in Beijing, China
Read
  • 15 December 2015
  • 1784
ACRES and Ethical GmbH, Switzerland to collaborate on eAdjudication
ACRES integrates eAdjudication into shared global platform of integrated technologies
Read
  • 10 December 2015
  • 2002
Widler & Schiemann to represent ACRES at EMA Inspectors Working Group
Peter Schiemann represented ACRES, the Alliance for Clinical Research Excellence and Safety at the EMA IWG Meeting on EDC systems and risk based monitoring in Clinical Trials
Read
  • 05 December 2015
  • 1748
ICH announces organizational changes!
The International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation (ICH) held the inaugural meetings of its new Assembly and Management Committee on 23 October 2015
Read the pdf Read
  • 02 December 2015
  • 1851
MHRA wants to see paper records retained
MHRA commented in their discussion forum on retention of trial records
Read more online Read
  • 21 November 2015
  • 1774
Survey on endpoint adjudication launched!
Mimmo Garibbo, Dirctor at Ethical GmbH launches survey on endpoint adjudication
Read more online Read
  • 17 November 2015
  • 383
2nd Academic Symposium on the Clinical Research Quality & China New Drug 50 Roundtable Forum in Beijing
Beat Widler will speak at the conference about "Development and Management New Trends of Global Clinical Research" on December 4th 2015
  • 14 November 2015
  • 2323
Beat Widler co-authors article on adjudication methods
An Overview and Analysis Regarding the Use of Adjudication Methods in EU and US Drug Approvals
Read the pdf Read
  • 07 November 2015
  • 1759
ICH goes Risk-based!
Beat Widler co-authors article in Applied Clinical Trials (ACT)
Read more online Read
  • 02 November 2015
  • 1803
CluePoints and Widler & Schiemann announce Partnership
CluePoints and WSQMS signed a partnership agreement to support each other in projects with clients
Read the pdf Read
  • 01 October 2015
  • 2264
Free Webinar on Implications of ICH E6 Amendment
In a webinar on October 20th, 2015, Clinerion and Widler & Schiemann will explain the implications of the ICH E6 Amendment on Managing Clinical Trials
Read more online Read
  • 01 October 2015
  • 1858
Workshop on Risk-based Monitoring
Artem Andrianov and Peter Schiemann to lead workshop at PCT Conference in November in Hamburg, Germany
Read the pdf Read
  • 01 October 2015
  • 1752
Cheaper Generics for poor Countries
European Commission backs bypassing drug patents for poor nations
Read more online Read
  • 31 August 2015
  • 2578
DIA Global Forum Online August
Contribution on Quality Matters by Beat Widler & Peter Schiemann
Read more online Read
  • 20 August 2015
  • 2157
EMA Draft Guideline on the Scientific Application and the practical Arrangements necessary to implement Regulation (EC) No 507/2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use falling within the Scope of Regulation (EC)
This draft guideline has been updated in order to reflect the experiences accumulated with conditional marketing authorisations and is therefore released for repeated public consultation.
Read the pdf Read
  • 15 August 2015
  • 1743
EMA Draft Guideline on the Scientific Application and the practical Arrangements necessary to implement the Procedure for accelerated Assessment pursuant to Article 14(9) of Regulation (EC) No 726/2004
EMA provides further clarification on the accelerated assessment procedure
Read the pdf Read
  • 10 August 2015
  • 2104
Beat Widler authors article on Inspection Readiness
The German Society for Pharmaceutical Medicine published an article by Beat Widler on Inspection Readiness (in German)
Read the pdf Read
  • 05 August 2015
  • 1790
FDA Draft Guidance on Metrics in Manufacturing
FDA released its draft guidance on metrics for manufacturing for comments within the next 60 days
Read the pdf Read
  • 31 July 2015
  • 455
E6 (R2) Addendum posted by ICH
This Integrated Addendum to ICH E6(R1) is proposed to modernise the ICH E6 Guideline by supplementing with additional recommendations which will facilitate broad and consistent international implementation of new methodologies.
Read the pdf
  • 31 July 2015
  • 2178
EMA to encourage use of Scientific Advice for Post-Authorisation Safety Studies
12-month pilot will support design of high-quality safety studies!
Read more online Read
  • 21 July 2015
  • 2583
FDA on early trials in Cellular and Gene Therapy Products
Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products
Read the pdf Read
  • 14 July 2015
  • 2078
FDA’s page on Expanded Access Programs
FDA’s current policies on compassionate use can be found on this homepage
Read more online Read
  • 08 July 2015
  • 398
Embrac­ing RBM, a company’s smaller size can become an advantage

RBM as Competitive Advantage for Mid-sized CROs (White Paper by A. Andrianov)

Read the pdf
  • 07 July 2015
  • 2005
Widler & Schiemann AG support WHO on GCP Training
Two successful workshops conducted in the Philippines and Nigeria
Read
  • 02 July 2015
  • 2192
FDA Releases Guidance for Acceptance of clinical Data from trials outside the USA
New Guidance issued by FDA for sponsors of medical devices who want to use their clinical data from trials outside the US for an FDA submission
Read the pdf Read
  • 20 June 2015
  • 2365
EMA on Gene Therapy
The European Medicines Agency invites feedback on their latest draft guidance
Read more online Read
  • 15 June 2015
  • 2011
Master Protocols proposed by FDA
FDA’s Woodcock proposes master protocols, infrastructure to increase clinical trial efficiency, reduce costs
Read more online Read
  • 10 June 2015
  • 2255
Beat Widler presents at Drug Development Expert Workshop in Frankfurt, Germany
Risk-based study management – dos and don’ts
Read the pdf Read
  • 05 June 2015
  • 479
WHO Workshop in Manila
Beat Widler conducts GCP Workshop on behalf of WHO in Manila
  • 05 June 2015
  • 1839
New FDA BIMO Slides are out!
The new Bioresearch Monitoring Metrics for 2014
Read more online Read
  • 01 June 2015
  • 2047
FDA Releases Guidance for Clinical Trial Sponsor-Investigators
New Guidance issued by FDA for investigators on how to file an IND (investigational new drug) application
Read the pdf Read
  • 20 May 2015
  • 1743
Endpoint Adjudication Methods used in Clinical Trials for 69% of the NMEs approved by FDA and 41% by EMA
Beat Widler with Ken Getz from Tufts University and colleagues from our partners published a research article on DIA’s Therapeutic Innovation & Regulatory Science, Journal
Read
  • 12 May 2015
  • 1691
WHO Statement on Public Disclosure of Clinical Trial Results
Ethical imperative and timeframe definitions
Read more online Read
  • 08 May 2015
  • 1970
Providing patients with outcomes of clinical trials
Initiatives to informing patients after their participation in a clinical trial of the outcome
Read more online Read
  • 04 May 2015
  • 2262
Faster Clinical Trial results reporting
Using TrialScope Convert can help you speed up your clinical trial results – and it is free!
Read more online Read
  • 03 May 2015
  • 2090
Clinical Trial Oversight Summit Boston
Peter Schiemann to speak at the Clinical Trial Oversight Summit, Boston, MA, June 1-3, 2015
Read more online Read
  • 30 April 2015
  • 2023
REMS Update
Modifications and Revisions on the FDA Guidance
Read the pdf Read
  • 20 April 2015
  • 1879
FDA invites comments on their Guidance for Clinical Trial Sponsors:
Establishment and Operation of Clinical Trial Data Monitoring Committees
Read more online Read
  • 15 April 2015
  • 2235
RbM Data reveals: Site screening Due Diligence improves patient dropout and retention
A way to utilize RbM for patient retention
Read more online Read
  • 10 April 2015
  • 1872
Case Study: Using RbM to evaluate and predict site engagement
RbM can do more than just deploy monitors
Read more online Read
  • 05 April 2015
  • 2056
FDA Draft Guidance on the use of electronic Informed Consent
A Q&A guide on the use of electronic Informed Consent in Clinical Investigations
Read the pdf Read
  • 31 March 2015
  • 520
Swiss Federal Office for Public Health launches new web site
The webpage has been completely revised and contains now also tools for researchers! These are the wizard to help categorise research projects, examples of trials and a glossary in four languages and more… Visit the website
  • 31 March 2015
  • 2107
Sentiment Analysis: Understand your Healthcare Customers
Beat Widler co-authors article on Applied Clinical Trials
Read more online Read
  • 21 March 2015
  • 1794
FDA - CTTI recommendations for GCP training
How frequently is GCP training needed and what should be included?
Read the pdf Read
  • 14 March 2015
  • 2193
EMA updated their Q&A on GCP webpage
How should data be presented when they are sent to the inspection team prior to a GCP inspection requested by the CHMP?
Read more online Read
  • 07 March 2015
  • 1888
Does the TransCelerate RbM Guidance Offer Standardization?
Beat Widler & Peter Schiemann quoted on Applied Clinical Trials Blog Post
Read more online Read
  • 26 February 2015
  • 1759
New FDA Draft Guidance on Expanded Access:
Individual Patient Expanded Access Applications: Form FDA 3926
Read the pdf Read
  • 23 January 2015
  • 459
RbM Guidance Document: Ten Burning Questions about Risk-Based Study Management
You can read this document and others in our Resources/Publications section. Read the pdf Visit the publications section
  • 14 January 2015
  • 1991
Applied Clinical Trials
RbM Guidance Document published on “Applied Clinical Trials”
Read it online Read
  • 10 January 2015
  • 1767
And finally another FDA Final Guidance for Industry
Providing Regulatory Submissions in Electronic Format-Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act
Read the pdf Read
  • 01 January 2015
  • 1797
Another FDA Final Guidance for Industry
Providing Regulatory Submissions In Electronic Format -Standardized Study Data
Read the pdf Read
  • 24 December 2014
  • 1833
Season's Greetings!
The whole Widler & Schiemann Ltd. team wishes you happy holidays and a successful and prosperous new year 2015!
Read
  • 22 December 2014
  • 1882
FDAs Final Guidance for Industry
Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products-Content and Format
Read the pdf Read
  • 18 December 2014
  • 2394
Exception From Informed Consent Requirements for Emergency Research
This is a 17 Nov 2014 update from the previous MAPP version dated 4 Feb 2003
Read the pdf Read
  • 09 December 2014
  • 2550
Rare Pediatric Disease Priority Review Vouchers - Guidance for Industry
FDA has published its draft guidance on rare pediatric disease priority review.
Read the pdfRead more online Read
  • 03 December 2014
  • 1824
European Guidelines on ePrescriptions
Guidelines on ePrescriptions were adopted by the European eHealth Network on 18th November 2014
Read more online Read
  • 14 November 2014
  • 2244
FDA GCP Training
The FDA conducts GCP training on site, but also provides on-line training and a whole training program
FDA Clinical Investigator Training CourseFDA's Clinical Investigator Training Course Read
  • 05 November 2014
  • 2244
New Data Dashboard Tool Shares FDA’s Inspection, Compliance and Recall Data
Inhalt: As part of FDAs commitment to transparency, FDA is pleased to announce that they have released a new online tool to provide insight into their compliance, inspection, and recall activities.
FDAs new dashboard Read
  • 03 February 2014
  • 673
Proposed changes to Directive 2001/20/EC
The European Commission, Parliament and Council published the proposal for repealing the Directive 2001/20/EC on "Clinical Trials on Medicinal products for Human Use". Download the document here:
Download as PDF
  • 01 December 2013
  • 685
Risk-based Quality Management
EMA publishes final version of their Reflection Paper on Risk-based Quality Management in Clinical Trials
Download it here!
  • 22 November 2013
  • 692
Clinical Quality Forum, Beijing, China
Beat presenting at the 1st International Forum on the Quality of Clinical Research, Beijing, 22 - 23 October 2013
Pictures on Flickr.com
  • 08 November 2013
  • 704
Q&A on Design Space Verification
EMA and FDA publish new guidance on adhering to QbD principles:
Download the PDF
  • 06 November 2013
  • 607
DIA Clinical Forum Dublin 2013
Peter Schiemann presented at the Clinical Forum in October 2013 about "A holistic Approach to Monitoring Clinical Trials". Download presentation here:
Download the Presentation
  • 12 October 2013
  • 808
Pharma Compliance Europe 2013
Wolfgang Beck was invited to speak at Pharma Compliance Europe 2013 about 'Service Honoraria at Fair Market Value'.
View the slides (pdf)
  • 10 October 2013
  • 794
"A Roadmap For Sharing Clinical Trial Data"
Widler & Schiemann AG invited to participate and represent ABPI at the EFPIA/PhRMA event on "A Roadmap For Sharing Clinical Trial Data"!
Conference Report Conference Website
  • 10 October 2013
  • 900
EFGCP, ACRES, EORTC and UCL organize a hands-on workshop
EFGCP, ACRES, EORTC and UCL organize a hands-on workshop on how to implement a risk based approach to managing quality in clinical trials
Download the pdf
  • 24 September 2013
  • 822
Swiss government approved the new ordinance regarding the Swiss clinical research law
Beat Widler was invited by the Federal Office of Public Health (BAG) to provide a critical assessment of the new ordinance. Read the article here (german):
Publication
You can subscribe to the WSQMS Newsletter here!

Services

Quality by Design

Our extensive track record and our close collaboration with regulators positions us uniquely to support clients in QbD projects with the latest development in methodologies and regulations.

Read Download as PDF
Quality Risk Management

As recognized experts in QRM we provide leading edge knowledge and support to clients developing and implementing a QRM approach.

Read Download as PDF
Risk-based Monitoring & Study Management

With the QbD and QRM methodologies we are in a unique position to help you design your new approach to a targeted and centralized monitoring and study management approach.

Read Download as PDF
SOP Management and Re-engineering

We have developed and successfully deployed a new approach to SOP management. Structured Content Management (SCM) allows tailoring the content of an SOP to the exact needs of each user group. With this we have created a whole set of clinical development SOPs that can easily be deployed in your company.

Read Download as PDF
Quality Strategy, Quality Policy & Quality Manuals

Many years of experience with large and small organizations developing Quality Strategies and key Quality documentation such as Quality Policy and Manual tailored to the customers specific needs.

Read Download as PDF
Design & Implementation of a Quality Management System

We have worked with large and small organizations and helped them develop and deploy a fit-for-purpose QMS. Their experience has allowed them to detect early obstacles or even resistance and to propose the right change management steps.

Read Download as PDF
GCP, Quality Risk Management & Quality Methodology Training

We are proud to be able to offer you tailored training courses as an in-house training for your staff either as refresher training or for newcomers.

Read Download as PDF
Service Provider & Vendor Qualification and Assessment

We have extensive experience in qualifying vendors and designing processes ranging from pre-contract assessments (risk based) to in process audits and quality risk assessments.

Read Download as PDF
GCP Issue Management

We have combined more than 35 years of experience in the GCP field and are viewed by many of our peers in the industry as thought-leaders in compliance matters and issues.

Read Download as PDF
Independent QA Support & Services

We have a demonstrated track record of successful implementations of QA plans and strategies as well as CAPA (Corrective and Preventive Action) programs and QA infrastructure and organizations.

Read Download as PDF
Inspection Readiness Support

We have developed and implemented processes to make organizations inspection ready. A toolkit has been developed to assist teams and functions to reach an inspection ready state.

Read Download as PDF
Quality Management of Pharmacovigilance Processes

We have developed a systematic approach to ensuring a continuous oversight on safety reporting whether in clinical trials or of spontaneous cases from marketed products. This methodology is based on the QbD and QRM principle and can be tailored to the customers' need.

Read Download as PDF
Corporate Compliance

With our experience we are best positioned to define the systems’ requirements, perform a risk analysis and define and rollout of processes for health care compliance.

Read Download as PDF
Regulatory Intelligence Clinical Quality & Risk Management

Through our network, we are uniquely placed to learn early of planned changes that may impact your operations and even more important we are able to put these in the right legal and regulatory context to guide you to make the right process and organizational changes or to confidently refuse any change.

Read Download as PDF
Contact

Widler & Schiemann AG can provide you with innovative, creative and cost effective answers to your questions and needs in the areas of Clinical Quality Management.

  • Weinberghöhe 10 B, CH 6300 Zug, Switzerland
  • +41 41 558 9193
  • info@wsqms.com

Recent Facebook Posts
Most Popular
Copyright Widler & Schiemann AG 2015. All Rights Reserved. /